Genmab A/S (ADR)
General ticker "GMAB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $14.5B (TTM average)
Genmab A/S (ADR) follows the US Stock Market performance with the rate: 53.3%.
Estimated limits based on current volatility of 1.1%: low 31.56$, high 32.28$
Factors to consider:
- Total employees count: 548 as of 2019
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [18.64$, 31.44$]
- 2025-12-31 to 2026-12-31 estimated range: [20.74$, 34.24$]
Financial Metrics affecting the GMAB estimates:
- Positive: with PPE of 16.6 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 31.14 > 18.64
- Negative: negative Industry operating cash flow (median)
- Negative: 0.01 < Interest expense per share per price, % of 0.13
- Positive: -14.38 < Investing cash flow per share per price, % of -10.41
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Positive: Return on assets ratio (scaled to [-100,100]) of 14.62 > 6.04
- Positive: 6.82 < Operating cash flow per share per price, % of 8.17
Short-term GMAB quotes
Long-term GMAB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | DKK14,505.00MM | DKK16,474.00MM | DKK21,526.00MM |
| Operating Expenses | DKK8,238.00MM | DKK11,153.00MM | DKK14,823.00MM |
| Operating Income | DKK6,267.00MM | DKK5,321.00MM | DKK6,703.00MM |
| Non-Operating Income | DKK678.00MM | DKK316.00MM | DKK2,461.00MM |
| Interest Expense | DKK21.00MM | DKK27.00MM | DKK120.00MM |
| R&D Expense | DKK5,562.00MM | DKK7,630.00MM | DKK9,748.00MM |
| Income(Loss) | DKK6,945.00MM | DKK5,637.00MM | DKK9,164.00MM |
| Taxes | DKK1,493.00MM | DKK0.00MM | DKK1,320.00MM |
| Profit(Loss)* | DKK3,869.00MM | DKK4,352.00MM | DKK7,844.00MM |
| Stockholders Equity | DKK27,282.00MM | DKK31,610.00MM | DKK36,697.00MM |
| Inventory | DKK0.00MM | DKK57.00MM | DKK62.00MM |
| Assets | DKK30,119.00MM | DKK35,289.00MM | DKK45,811.00MM |
| Operating Cash Flow | DKK3,912.00MM | DKK7,380.00MM | DKK7,771.00MM |
| Capital expenditure | DKK317.00MM | DKK376.00MM | DKK187.00MM |
| Investing Cash Flow | DKK-2,761.00MM | DKK-1,282.00MM | DKK-9,907.00MM |
| Financing Cash Flow | DKK-789.00MM | DKK-606.00MM | DKK-3,919.00MM |
| Earnings Per Share** | DKK5.92 | DKK6.60 | DKK12.14 |
| Ordinary share to ADR | 10.00x | 10.00x | 10.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.